Ergoloid Mesylate ( DrugBank: Ergoloid mesylate )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 206 | 脆弱Ｘ症候群 | 1 |
206. 脆弱Ｘ症候群
臨床試験数 : 108 / 薬物数 : 91 - (DrugBank : 36) / 標的遺伝子数 : 52 - 標的パスウェイ数 : 77
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05030129 (ClinicalTrials.gov) | October 7, 2021 | 5/8/2021 | Single Blind Study of Ergoloid Mesylates, 5-HTP and the Combination in Adult Males With Fragile X Syndrome | An Exploratory Single Blind Study of Ergoloid Mesylates, 5-Hydroxytryptophan, and the Combination in Adult Males With Fragile X Syndrome | Fragile X Syndrome | Dietary Supplement: 5-Hydroxytryptophan / Vitamin B6;Drug: Ergoloid Mesylate;Other: Placebo | Elizabeth Berry-Kravis | NULL | Recruiting | 18 Years | 45 Years | Male | 15 | Phase 2 | United States |